Earnings Call · Q2 FY2022·2022-08-08

Q2 22EPS +22.45%·Rev n/aQ1 22EPS +12.07%·Rev n/aQ4 21EPS +100.00%*·Rev n/aQ3 21EPS -100.00%*·Rev n/a⚠ consensus missing

Atea Pharmaceuticals, Inc. AVIR

Jonae Barnes — Investor Relations or Communications

Jean-Pierre Sommadossi — Chief Executive Officer (CEO)

Janet Hammond — Executive (likely clinical or medical affairs) based on discussing clinical trials and programs

Andrea Corcoran — Executive (likely finance) based on discussing financial results

−1.3%1d on move date−0.9% vs SPY3d−4.2%5d−0.1%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more AVIR calls or request research access.

More AVIR calls Browse calls Request research access